Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2

Cancer Science

Volumn 99, Issue 8, 2008, Pages 1603-1610

  Yamada, Tadaaki ^a   Yano, Seiji ^a,b   Ogino, Hirokazu ^a   Ikuta, Kenji ^a   Kakiuchi, Soji ^a   Hanibuchi, Masaki ^a   Kanematsu, Takanori ^a   Taniguchi, Tetsuo ^c   Sekido, Yoshitaka ^c   Sone, Saburo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; LYSOPHOSPHATIDIC ACID RECEPTOR 2; LYSOPHOSPHATIDIC ACID RECEPTOR 3; LYSOPHOSPHATIDIC ACID RECEPTOR 4; LYSOPHOSPHATIDIC ACID RECEPTOR 5; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; RNA SEQUENCE;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOXAZOLES; LYSOPHOSPHOLIPIDS; MESOTHELIOMA; PLEURAL NEOPLASMS; PROPIONIC ACIDS; RECEPTORS, LYSOPHOSPHATIDIC ACID;

EID: 49749144775     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00848.x     Document Type: Article

References (42)

1. Broaddus VC. Asbestos, the mesothelial cell and malignancy: A matter of life or death. Am J Respir Cell Mol Biol 1997; 17: 657-9.
2. Morinaga K, Kishimoto T, Sakatani M, Akira M, Yokoyama K, Sera Y. Asbestos-related lung cancer and mesothelioma in Japan. Industrial Health 2001; 39: 65-74.
3. Dufresne A, Bégin R, Churg A, Massé S. Mineral fiber content of lungs in patients with mesothelioma seeking compensation in Quebec. Am J Respir Crit Care Med 1996; 153: 711-18.
4. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002; 29: 2-17.
5. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-603.
6. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 1993; 291: 677-80.
7. Gerrard JM, Robinson P. Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombin. Biochim Biophys Acta 1989; 1001: 282-5.
8. Shen Z, Belinson J, Morton RE, Xu Y, Xu Y. Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. Gynecol Oncol 1998; 71: 364-8.
9. Aoki J, Taira A, Takanezawa Y et al. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem 2002; 277: 48737-44.
10. Siess W, Zangl KJ, Essler M et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci USA 1999; 96: 6931-6.
11. Fang X, Schummer M, Mao M et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 2002; 1582: 257-64.
12. Mills GB, May C, Hill M, Campbell S, Shaw P, Marks A. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest 1990; 86: 851-5.
13. Xu Y, Gaudette DC, Boynton JD et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1995; 1: 1223-32.
14. Contos JJ, Ishii I, Chun J. Lysophosphatidic acid receptors. Mol Pharmacol 2000; 58: 1188-96.
15. Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 2003; 278: 25.600-6.
16. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 2006; 281: 23.589-97.
17. An S, Bleu T, Hallmark OG, Goetzl EJ. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem 1998; 273: 7906-10.
18. Bandoh K, Aoki J, Hosono H et al. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem 1999; 274: 27776-85.
19. Kishi Y, Okudaira S, Tanaka M et al. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 2006; 281: 17492-500.
20. Shida D, Watanabe T, Aoki J et al. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab Invest 2004; 84: 1352-62.
21. Schulte KM, Beyer A, Köhrer K, Oberhäuser S, Röher HD. Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: Over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer. Int J Cancer 2001; 92: 249-56.
22. Kitayama J, Shida D, Sako A et al. Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res 2004; 6: R640-6.
23. Mills GB, Eder A, Fang X et al. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res 2002; 107: 259-83.
24. Shida D, Kitayama J, Yamaguchi H et al. Dual mode regulation of migration by lysophosphatidic acid in human gastric cancer cells. Exp Cell Res 2004; 301: 168-78.
25. Guo R, Kasbohm EA, Arora P et al. Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology 2006; 147: 4883-92.
26. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci USA 2006; 103: 9643-8.
27. Goetzl EJ, Dolezalova H, Kong Y et al. Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res 1999; 59: 5370-5.
28. Shida D, Kitayama J, Yamaguchi H et al. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res 2003; 63: 1706-11.
29. Yamada T, Sato K, Komachi M et al. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem 2004; 279: 6595-605.
30. Yokoyama A, Kohno N, Fujino S et al. Origin of heterogeneity of interleukin-6 (IL-6) levels in malignant pleural effusions. Oncol Rep 1994; 1: 507-11.
31. Nakataki E, Yano S, Matsumori Y et al. Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. Cancer Sci 2006; 97: 183-91.
32. Usami N, Fukui T, Kondo M et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci 2006; 97: 387-94.
33. Yano S, Muguruma H, Matsumori Y et al. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice. Clin Cancer Res 2005; 11: 8789-98.
34. Ohta H, Sato K, Murata N et al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 2003; 64: 994-1005.
35. Lindholm PM, Salmenkivi K, Vauhkonen H et al. Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH. Cytogenet Genome Res 2007; 119: 46-52.
36. Harvey I, Pass Zhandong L, Anil W et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 2004; 10: 849-59.
37. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003; 3: 582-91.
38. Stähle M, Veit C, Bachfischer U et al. Mechanisms in LPA-induced tumor cell migration: Critical role of phosphorylated ERK. J Cell Sci 2003; 116: 3835-46.
39. Hama K, Aoki J, Fukaya M et al. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem 2004; 279: 17634-9.
40. Do TV, Symowicz JC, Berman DM et al. Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells. Mol Cancer Res 2007; 5: 121-31.
41. Michiels F, Habets GG, Stam JC, van der Kammen RA, Collard JG. A role for Rac in Tiam1-induced membrane ruffling and invasion. Nature 1995; 375: 338-40.
42. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 1999; 5: 221-5.